Hormonal
GLP-1 receptor agonists (specifically liraglutide 3.0 mg) produce clinically significant weight loss in overweight or obese individuals through reduced appetite and energy intake, rather than increased energy expenditure.
If you are overweight or obese, GLP-1 receptor agonists like liraglutide (3.0 mg daily) are a clinically proven tool for weight loss. They work by making you feel fuller and reducing your desire to eat, not by speeding up your metabolism. Treatment involves starting at a low dose and slowly increasing it to manage side effects. This intervention is most effective when combined with your usual lifestyle habits, though significant weight loss occurs even without strict diet changes in some studies.
Thus, the evidence supports reduced appetite and food intake, without an increase in energy expenditure, as the mechanism underlying weight loss with liraglutide.
Why this rating
Based on phase III clinical trials and FDA approval, though long-term outcome data was still emerging at the time of publication (2015).
Source
<scp>GLP</scp>‐1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond
Donna H. Ryan et al. · Obesity · 2015
DOI 10.1002/oby.21107
More from this paper
- GLP-1 receptor agonists provide cardiovascular benefits, including reduced blood pressure and improved endothelial function, which may occur independently of weight loss.Moderate
- GLP-1 receptor agonists exhibit neuroprotective effects in animal models of Alzheimer's and Parkinson's disease, potentially by crossing the blood-brain barrier and reducing amyloid-beta accumulation.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →